Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Company Overview - Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer and other conditions [1][5] - The company is advancing a pipeline of novel therapies, including its lead product candidate, palazestrant (OP-1250), which is currently in two Phase 3 clinical trials [5] Public Offering Announcement - Olema announced plans to commence a public offering of its common stock, which may include pre-funded warrants for certain investors [1] - The offering is subject to market conditions and will be managed by TD Cowen as the book-running manager [2] Offering Details - The proposed offering includes a 30-day option for underwriters to purchase up to an additional 15% of the total number of shares being offered [2] - The offering is made pursuant to a shelf registration statement filed with the SEC on January 6, 2025, and declared effective on January 15, 2025 [3]